Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 2;7(12):6291-312.
doi: 10.3390/v7122938.

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Samantha Turnbull  1 , Emma J West  2 , Karen J Scott  3 , Elizabeth Appleton  4 , Alan Melcher  5 , Christy Ralph  6
Affiliations
Review

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Samantha Turnbull et al. Viruses. .

Abstract

The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.

Keywords: HSV; clinical trials; immunotherapy; oncolytic virus; reovirus; vaccinia.

PubMed Disclaimer

References

    1. Moore A.E. Viruses with oncolytic properties and their adaptation to tumours. Ann. N. Y. Acad. Sci. 1952;54:945–952. doi: 10.1111/j.1749-6632.1952.tb39969.x. - DOI - PubMed
    1. Andtbacka R.H.I., Kaufman H.L., Collichio F., Amatruda T., Senzer N., Chesney J., Delman K.A., Spitler L.E., Puzanov I., Agarwala S.S., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 2015;33:2780–2788. doi: 10.1200/JCO.2014.58.3377. - DOI - PubMed
    1. Kanerva A., Nokisalmi P., Diaconu I., Koski A., Cerullo V., Liikanen I., Tähtinen S., Oksanen M., Heiskanen R., Pesonen S., et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin. Cancer Res. 2013;19:2734–2744. doi: 10.1158/1078-0432.CCR-12-2546. - DOI - PubMed
    1. Morse M.A., Chaudhry A., Gabitzsch E.S., Hobeika A.C., Osada T., Clay T.M., Amalfitano A., Burnett B.K., Devi G.R., Hsu D.S., et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. Immunother. 2013;62:1293–1301. doi: 10.1007/s00262-013-1400-3. - DOI - PMC - PubMed
    1. Pesonen S., Diaconu I., Kangasniemi L., Ranki T., Kanerva A., Pesonen S.K., Gerdemann U., Leen A.M., Kairemo K., Oksanen M., et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: Assessment of safety and immunologic responses in patients. Cancer Res. 2012;72:1621–1631. doi: 10.1158/0008-5472.CAN-11-3001. - DOI - PubMed

Publication types